Shanghai Leo Pharmaceutical Consulting

Leo Pharma is a global pharmaceutical company dedicated to advancing the standard of care for people with skin conditions. Headquartered in Denmark, the company has a significant presence in China through Shanghai Leo Pharmaceutical Consulting, which manages its regional operations and medical affairs. The company specializes in medical dermatology, offering a robust portfolio of treatments for psoriasis, atopic dermatitis, eczema, and skin infections. Key products include the biologic Adtralza (tralokinumab) and the topical combination Enstilar. Leo Pharma is majority-owned by the LEO Foundation, which supports its mission to provide innovative solutions for dermatological patients worldwide. The company continues to expand its pipeline with a focus on both topical and systemic therapies for chronic skin diseases.